Clinical Trials

By Marta Catalfamo

Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure (Virginia-ART4)

Principal Investigators: Benjamin Van Tassell, PharmD. Virginia Commonwealth University. Richmond, Virginia, United States, 23298

Contact: Benjamin Van Tassell, PharmD. Phone: 804-828-4583

ClinicalTrials.gov Identifier: NCT05177822

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Principal Investigators: John R. Perfect, MD. Duke University. Durham, North Carolina, United States, 27708

Contact: John R. Perfect, MD. Phone: (919) 684-4016

ClinicalTrials.gov Identifier: NCT04979052

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients (IGNORANT)

Principal Investigators: Anne-Claire LUKASZEWICZ, Pr. Hospices Civils de Lyon. Service civilo-militaire d’Anesthésie-Réanimation et Médecine Périopératoire. Lyon, France, 69003.

Contact: Camille BOUCHENY. Phone: 4 26 73 27 39 ext +33

ClinicalTrials.gov Identifier: NCT05843786

Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study (COV-NI)

Principal Investigators: Jean-Philippe Lanoix, MD. Centre Hospitalier Universitaire, Amiens. Amiens, France, 80480

Contact: Aurélien Mary, MD. Phone: (33)22087140

ClinicalTrials.gov Identifier: NCT04469491

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Principal Investigators: Diwakar Davar, MD. University of Pittsburgh Cancer Institute (UPCI). Pittsburgh, Pennsylvania, United States, 15232

Contact: Diwakar Davar, MD. Phone: 412-647-8073    

ClinicalTrials.gov Identifier: NCT03030378

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)

Principal Investigators: Andrej SPEC, MD. Washington University School of Medicine. Saint Louis, Missouri, United States, 63110

Contact: Andrej SPEC, MD. Phone: 314.747.1725

ClinicalTrials.gov Identifier: NCT04154826

Study of SRF388 in Patients With Advanced Solid Tumors

Principal Investigators: Arpita Desai, MD. UCSF Medical Center – Helen Diller Family Comprehensive Cancer Center. San Francisco, California, United States, 94143  

Contact: Ria Conti, Phone: 415-514-2259

ClinicalTrials.gov Identifier: NCT04374877

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma

Principal Investigators: Tannaz Armaghany, MD. Baylor College of Medicine. Houston Methodist Hospital. Houston, Texas, United States, 77030.

Contact: Tannaz Armaghany. Phone: 713-798-3750

ClinicalTrials.gov Identifier: NCT05103631

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Principal Investigators: Naoko Takebe, M.D. National Institutes of Health Clinical Center. Bethesda, Maryland, United States, 20892

Contact: Ashley B Bruns. Phone: (240) 858-3162

ClinicalTrials.gov Identifier: NCT03388632

Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 (ILIAD)

Principal Investigators: Jordan Feld, MD. University Health Network. Toronto, Ontario, Canada, M5G 2C4

Contact: Bethany Barber.  Phone: 416-340-4800 ext 6569

ClinicalTrials.gov Identifier: NCT04354259

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)

Principal Investigators:

Contact: Phone:

ClinicalTrials.gov Identifier: NCT05049798

Ph1 Trial Test Safety of IL-21 NK Cells for Induction of R/R AML

Principal Investigators: Sumithira Vasu, MBBS. Ohio State University Comprehensive Cancer Center. Columbus, Ohio, United States, 43210

Contact: Sumithira Vasu, MBBS.  Phone: 614-293-8197

ClinicalTrials.gov Identifier: NCT04220684